Journal
BIOMEDICINES
Volume 10, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines10051141
Keywords
Rab GTPases; Alzheimer's; neurodegeneration
Categories
Funding
- College of Life Sciences, University of Leicester, UK
- Lewy Body Society [LBS-LBS-0007]
- Medical Research Council [MR/R011621/1]
- Leicester Research Archive, University of Leicester
Ask authors/readers for more resources
This review highlights the important roles of Rab GTPases in vesicle transport and membrane trafficking, and their implications in the pathogenesis of various diseases. It also provides an overview of the current state of pharmacological targeting of Rabs and discusses the challenges of therapeutically targeting these small proteins in humans, particularly in the context of Alzheimer's disease.
Rab GTPases (Rabs) are small proteins that play crucial roles in vesicle transport and membrane trafficking. Owing to their widespread functions in several steps of vesicle trafficking, Rabs have been implicated in the pathogenesis of several disorders, including cancer, diabetes, and multiple neurodegenerative diseases. As treatments for neurodegenerative conditions are currently rather limited, the identification and validation of novel therapeutic targets, such as Rabs, is of great importance. This review summarises proof-of-concept studies, demonstrating that modulation of Rab GTPases in the context of Alzheimer's disease (AD) can ameliorate disease-related phenotypes, and provides an overview of the current state of the art for the pharmacological targeting of Rabs. Finally, we also discuss the barriers and challenges of therapeutically targeting these small proteins in humans, especially in the context of AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available